At a cumulative annual growth rate (CAGR) of 5.9%, the breast reconstruction surgery and therapies market sale is expected to have grown from US$ 853.9 million in 2022 to US$ 1.61 billion by the end of 2033.
This increase reflects the growing recognition and significance of breast reconstruction treatments as essential components of care following a mastectomy. The market is expanding as a result of improvements in surgical methods and a rising emphasis on patient-centric approaches. The market is expected to play a significant role in improving the quality of life for breast cancer survivors and creating a favourable outlook for the future of reconstructive surgery and therapy as the need for customised and all-inclusive breast reconstruction solutions grows.
Breast augmentation, also referred to as breast reconstruction, consists of areola and remodelling of the nipples. The majority of patients with breast reconstruction are female. Three categories exist for breast reconstruction: tissue and implant reconstruction, implants/prosthetic reconstruction, and autologous tissue reconstruction.
Implants/prosthetic breast reconstruction refers to breast reconstruction with artificial implants. When a portion of tissue from another part of the body is utilised to reconstruct the breast, this is referred to as autologous tissue breast reconstruction. For breast augmentation, either autologous tissue reconstruction, implants/prosthetic reconstruction, or both forms of reconstruction are employed.
Women who have had breast reconstruction face a variety of complications.
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-14393
Breast reconstruction with silicone and saline is usually associated with complications. Breast reconstruction is often performed for cosmetic reasons or to restore lost breast volume due to pregnancy, weight loss, or mastectomy for breast cancer. Breast reconstruction surgery is the finest option for breast reconstruction.
Breast reconstruction is performed when the entire breast or a portion of the breast is removed.
They help with coping with breast loss caused by cancer and are also used for cosmetic purposes. The patient should have adequate privacy during breast reconstruction surgery.
Advancing Innovations in Breast Reconstruction: A Landscape of Opportunities for Surgery and Treatment Manufacturers:
Because of the launch of 3D-printed implants, the market for Breast Reconstruction Surgery and Treatments may witness a large boost. BellaSeno and Evonik, both of Germany, have joined together to develop 3D breast implant technology.
BellaSeno’s Senella breast scaffolds will be made of Evonik’s Resomer bioresorbable polymer, replacing silicone implants, which have prompted serious safety concerns.
According to BellaSeno and Resomer’s plans, the first human clinical investigations using the Senella scaffolds would begin in Germany in 2019. Evonik has also made their Resomer polymer available for commercial and clinical use.
The scaffolds, made of liposuctioned human fat, are intended to drive the growth of healthy tissue. This product is intended for usage following surgery for augmentation, reconstruction, or revision. The body progressively absorbs this and replaces it with native breast tissue.
Breast Reconstruction Surgery and Treatment Market Regional Insights:
In 2023, the United States is expected to represent approximately 32.0% of the global market.
Because of the high prevalence of breast cancer, rising breast augmentation operations, and sophisticated healthcare infrastructure in the United States, the market is expanding.
According to the American Society of Plastic Surgeons’ 2020 report, breast augmentation was one of the top five cosmetic surgery treatments in the United States in 2020. The region’s breast implant market is expected to grow as the incidence of breast cancer rises. According to the GLOBOCAN 2020 survey, there have been 253,465 new cases of breast cancer in the USA region.
Germany is expected to have 5.9% of the global market in 2023. The key factor driving the regional market is the increased prevalence of breast cancer. According to the World Health Organisation, approximately 69,697 new cases of breast cancer were discovered in Germany in 2020. Breast reconstruction surgeries are in high demand due to the increased global incidence of breast cancer. Breast Reconstruction Surgery and Treatment are becoming more popular as a result of rising hereditary disorders in women, rising healthcare expenditures, and changes in government policy.
Over the predicted period, China is expected to grow at a CAGR of 3.3%. Both the increased knowledge of breast reconstruction surgery and the rapidly growing breast cancer population are to blame for the increase. For example, according to NCBI data, there were around 303,600 new cases of breast cancer and 70,400 deaths from the disease in China.
Breast Reconstruction Surgery and Treatment Market Competitive Landscape:
The market for Breast Reconstruction Surgery and Treatment is competitive, with several established companies. Numerous firms utilise strategies such as geographic expansion, mergers and acquisitions, collaborations, and the launch of new goods to enhance their market share. A sizable distributor marketing network benefits players in both global and local markets.
Breast Reconstruction Surgery and Treatment Market Recent Developments:
- Mentor Worldwide LLC (Johnson & Johnson) will receive FDA approval for a new MENTOR Memory Gel improve breast implant in 2022.
- The FDA approved POLYTECH Health & Aesthetics’ textured breast implants in 2021. (Macrotextured implants with a polyurethane coating)
Request Report Methodology:https://www.futuremarketinsights.com/request-report-methodology/rep-gb-14393
Breast Reconstruction Surgery and Treatment Market Major Players:
- Mentor Worldwide LLC (Johnson & Johnson)
- Allergan Aesthetics (An AbbVie Company)
- Sientra
- POLYTECH Health & Aesthetics GmbH
- GC Aesthetics
- Sebbim
- Establishment Labs S.A.
- Integra Lifesciences
Key Segments :
Product:
- Breast Implants
- Silicone Implants
- Saline Implants
- Tissue Expanders
- Acellular Dermal Matrix
Procedure:
- Immediate
- Delayed
- Revision
Surgery:
- Unilateral
- Bilateral
End-User:
- Hospitals
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
